Chakra Biotech Sdn Bhd Completes Series B Investment Round
31-Mar-2010
- Malaysia
Chakra Biotech CEO Anthony Bishop said, "The Series B investment is a strong sign of the confidence we share with our investors that our full range of service offerings are valuable to our customers, particularly our proprietary chakragati (ckr) mouse model for screening new psychiatric drugs."
The ckr mouse model is a US Patented transgenic model of psychiatric disease.
Most read news
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.